Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure
Status:
Completed
Trial end date:
2019-01-30
Target enrollment:
Participant gender:
Summary
Now many cases reported failure to HCV treatment with Sofosbuvir/ Daclatasvir. retreat those
patients is challenging. So, we aimed to Study the efficacy and safety of Sofosbuvir
/Simeprevir/ Daclatasvir/Ribavirin versus Sofosbuvir /ombitasvir/
paritaprevir/ritonavir/ribavirin in the management of hepatitis C patients who failed to
prior Sofosbuvir/ Daclatasvir regimens in an open-labeled randomized trial.